Physician profile
Simin Nasr
NPI 1578069134
$311.84
in general payments reported to CMS, 2019-2025
10 companies · $18.76 in 2025
The $18.76 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $41.58 · 2023: $179 · 2024: $72.08 · 2025: $18.76.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $48.83 | 2023 | |
| Alexion Pharmaceuticals, INC. | $48.78 | 2023-2025 | Ultomiris, Soliris |
| Astrazeneca Pharmaceuticals Lp | $45.28 | 2023-2024 | Flumist Quadrivalent, Farxiga |
| Janssen Biotech, INC. | $41.58 | 2022 | |
| Novo Nordisk INC | $40.48 | 2023-2024 | Ozempic, Wegovy |
| Insulet Corporation | $29.78 | 2023 | Omnipod |
| Glaxosmithkline, LLC. | $17.54 | 2023 | Bexsero, Rotarix, Pediarix |
| Medtronic, INC. | $17.32 | 2024 | Minimed 780g |
| Otsuka America Pharmaceutical, INC. | $16.26 | 2023 | Rexulti |
| Organon LLC | $5.99 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simin Nasr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.